DataString Consulting Company Logo
DataString Consulting Company Logo
Guanfacine Hydrochloride Market
Home»Top Market Reports»Guanfacine Hydrochloride Market

Guanfacine Hydrochloride Market

Author: Debadatta Patel - Senior Consultant, Report ID - DS1802249, Published - May 2025

Segmented in Prescription Type (Extended-Release, Immediate-Release), Application Areas (ADHD, Hypertension, Anxiety Disorders, Sleep Disorders, Other CNS Disorders), Patient Demographics, Therapy Type, Distribution Channel and Regions - Global Industry Analysis, Size, Share, Trends, and Forecast 2024 – 2034

Share this report:

Global Guanfacine Hydrochloride
Market Outlook

The market, for Guanfacine hydrochloride was estimated at $498.1 million in 2024; and it is anticipated to increase to $812.6 million by 2030 with projections indicating a growth to around $1.2 billion by 2035. This expansion represents a compound annual growth rate (CAGR) of 8.5% over the forecast period. The continuous rise in demand for Guanfacine Hydrochloride in the market reflects its growing importance in modern healthcare practices and treatments today. Several factors contribute to this trend; ongoing advancements in the pharmaceutical industry and a deeper appreciation for the therapeutic advantages offered by this substance. Moreover clinical conditions like Hypertension and Attention deficit hyperactivity disorder (ADHD) are becoming more prevalent contributing to the growth of the market for targeted and effective treatments. Overall indicating the enduring significance of this pharmaceutical component, in addressing pressing medical needs effectively.


Known for its effectiveness and minimal side effects in prescriptions Guanfacine Hydrochloride plays a crucial role in the medical field as an antihypertensive medication and in treating ADHD symptoms too It is widely used across different industries due to its versatility The recent trend of incorporating Guanfacine Hydrochloride in new dosage forms and exploring its potential in pediatric medicine is driving the demand, for this medication.


Market Size Forecast & Key Insights

2019
$498M2024
2029
$1.1B2034

Absolute Growth Opportunity = $628M

The Guanfacine Hydrochloride market is projected to grow from $498.1 million in 2024 to $1.13 billion in 2034. This represents a CAGR of 8.5%, reflecting rising demand across Treatment for High Blood Pressure, Attention Deficit Hyperactivity Disorder (ADHD) Management and Severe Pain Management.

The Guanfacine Hydrochloride market is set to add $628 million between 2024 and 2034, with manufacturer targeting Hypertension & Anxiety Disorders Application Areas projected to gain a larger market share.

With Increasing prevalence of adhd, and Technological advancements in drug formulation, Guanfacine Hydrochloride market to expand 126% between 2024 and 2034.

Opportunities in the Guanfacine Hydrochloride Market

Customer Awareness and Education

ADHD is commonly. Not properly addressed in various regions despite its widespread occurrence. By using platforms effectively in awareness campaigns can help dispel misunderstandings, about ADHD and showcase the effectiveness of Guanfacine Hydrochloride in managing the condition.

Expansion Into Underserved Regions and Technological Advancements in the Pharmaceutical Sector

The potential of Guanfacine Hydrochloride in growing markets is significant as awareness and acceptance of ADHD treatments are gradually increasing in regions such as India, China and Brazil due to the expanding middle class population and rising healthcare spending levels. Forming partnerships, with organizations strategically can address challenges and facilitate quicker market entry.

Further advancements in drug delivery methods have the potential to revolutionize the use of Guanfacine Hydrochloride for treating ADHD on a level. With a focus on tailoring treatments to patient needs in mind innovative technologies like controlled release capsules and accurate dosaging systems show great potential for enhancing treatment effectiveness. Customized medication regimens could lead to improved results and encourage the wider use of Guanfacine Hydrochloride, in medical practice.

Growth Opportunities in North America and Asia-Pacific

Asia Pacific Outlook

With the healthcare industry growing and cities developing in the Asia Pacific regions market for Guanfacine Hydrochloride is set to see substantial growth ahead due to rising awareness of mental health issues such as ADHD in countries like China and India leading to more prescriptions being issued. The competitive landscape is fierce, with the presence of generic drug companies intensifying the market competition. Promising avenues in the region involve forming collaborations with local pharmaceutical firms for manufacturing and distribution purposes. Additionally leveraging progress to improve product effectiveness and meeting the demand for cost effective treatments, in emerging markets are crucial strategies.

North America Outlook

The Guanfacine Hydrochloride market in North America is prospering thanks to the rising cases of conditions such as ADHD and hypertension. The United States stands out as the market in the region because of its strong healthcare system and wide range of treatment options available. With advancements in technology and a growing awareness of mental health issues there has been a noticeable increase in prescriptions for Guanfacine Hydrochloride. However the competition, among established pharmaceutical companies producing this vital compound remains fierce. There are chances in improving production procedures creating prolonged release variations and investigating extra medical applications, for Guanfacine Hydrochloride.

North America Outlook

The Guanfacine Hydrochloride market in North America is prospering thanks to the rising cases of conditions such as ADHD and hypertension. The United States stands out as the market in the region because of its strong healthcare system and wide range of treatment options available. With advancements in technology and a growing awareness of mental health issues there has been a noticeable increase in prescriptions for Guanfacine Hydrochloride. However the competition, among established pharmaceutical companies producing this vital compound remains fierce. There are chances in improving production procedures creating prolonged release variations and investigating extra medical applications, for Guanfacine Hydrochloride.

Asia-Pacific Outlook

With the healthcare industry growing and cities developing in the Asia Pacific regions market for Guanfacine Hydrochloride is set to see substantial growth ahead due to rising awareness of mental health issues such as ADHD in countries like China and India leading to more prescriptions being issued. The competitive landscape is fierce, with the presence of generic drug companies intensifying the market competition. Promising avenues in the region involve forming collaborations with local pharmaceutical firms for manufacturing and distribution purposes. Additionally leveraging progress to improve product effectiveness and meeting the demand for cost effective treatments, in emerging markets are crucial strategies.

Growth Opportunities in North America and Asia-Pacific

Established and Emerging Market's Growth Trend 2025–2034

1

Major Markets : U.S., China, Japan, Germany, India are expected to grow at 6.2% to 8.9% CAGR

2

Emerging Markets : Indonesia, Brazil, South Africa are expected to grow at 8.2% to 10.6% CAGR

Market Analysis Chart

As an integral compound in the pharmaceutical sector, Guanfacine Hydrochloride has been experiencing a surge in demand. This increase is a prominent market driver stimulated by the compounds efficacy in treating various conditions such as attention deficit hyperactivity disorder and high blood pressure. Moreover, the compounds evolving application in the healthcare sector as a nerve signal inhibitor also contributes to its increasing market strength.

Recent Developments and Technological Advancement

December 2024

AP Pharma has released an extended-release formulation of Guanfacine Hydrochloride, designed to provide patients with prolonged relief from symptoms of ADHD without frequent re-dosing

September 2024

HealthCore Incorporated revealed a novel method for synthetically creating Guanfacine Hydrochloride, potentially leading to reduced manufacturing costs and increased access to patients globally

June 2024

Sanderson Biogenics announced they had successfully completed clinical trials for a more precise Guanfacine Hydrochloride dosage system, aiming to minimize adverse effects and enhance the treatment experience for patients.

Guanfacine Hydrochloride, a drug primarily utilized in the treatment of ADHD and hypertension, has been witnessing significant market developments recently. One of the primary applications of Guanfacine Hydrochloride is in the realm of neurologic disorder management, with impressive efficacy in attenuating symptoms of Attention deficit hyperactivity disorder .

Impact of Industry Transitions on the Guanfacine Hydrochloride Market

As a core segment of the Pharmaceutical industry, the Guanfacine Hydrochloride market develops in line with broader industry shifts. Over recent years, transitions such as Evolving Mental Health Outlook and Advancements in Drug Delivery Systems have redefined priorities across the Pharmaceutical sector, influencing how the Guanfacine Hydrochloride market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.

1

Evolving Mental Health Outlook:

The changing views on health conditions like Attention Deficit Hyperactivity Disorder have had a significant impact on the Guanfacine Hydrochlorideindustry'strajectory. Guanfacine Hydrochloride has seen a surge in demand due to its increased use in treating ADHD symptoms—a trend attributed to its recognized benefits and safety record. These positive aspects have positioned Guafacine Hydrochloride for growth, within the behavioral health sector. The shift towards personalized patient care focusing on health has certainly boosted Guanfacine Hydrochlorides popularity, in the medical field.

2

Advancements in Drug Delivery Systems:

The pharmaceuticalindustry'smodernization has led to considerable advancements in drug delivery systems. These evolutions have been instrumental in enhancing the efficacy of drugs like Guanfacine Hydrochloride.

Global Events Shaping Future Growth

The chart below highlights how external events including emerging market developments, regulatory changes, and technological disruptions, have added another layer of complexity to the Pharmaceutical industry. These events have disrupted supply networks, changed consumption behavior, and reshaped growth patterns. Together with structural industry transitions, they demonstrate how changes within the Pharmaceutical industry cascade into the Guanfacine Hydrochloride market, setting the stage for its future growth trajectory.

Market Dynamics and Supply Chain

Driver: Increasing Prevalence of ADHD, and Off-Patent Opportunities for Generic Drugs

The increasing worldwide prevalence of Attention Deficit Hyperactivity Disorder is also leading to a growing need, for Guanfacine Hydrochloride—a medication that helps in the treatment of this disorder by addressing impulsive actions and attention difficulties commonly linked to ADHD.
As the original patents for Guanfacine Hydrochloride have also expired, this has also paved the way for the production of generic versions. With more manufacturers able to produce Guanfacine Hydrochloride, its growing accessibility and affordability are also leading to a more prominent market presence.
Progress, in the field of pharmaceutical technology is also making it possible to create Guanfacine Hydrochloride in to take and more effective forms. For example extended release tablets are also now available that provide drug release over a period of time thereby strengthening the market standing of Guanfacine Hydrochloride.

Restraint: Regulatory Challenges

When Guanfacine Hydrochloride is prescribed as a medicine by doctors or healthcare professionals it goes through checks and strict quality measures to ensure its safety and efficacy. This extensive validation process can sometimes cause delays or stoppages in production if certain standards are not only met. Constant changes in guidelines across various countries further complicate matters and may affect the overall demand, for this particular medication.

Challenge: High Costs of Production

The production process of Guanfacine Hydrochloride involves the use of several high-cost raw materials and complex procedures. This implicates a higher cost of production for the drug, which inadvertently impacts the final pricing. Consequently, the higher price might deter some of the potential customers, acting as a significant to the market demand and dynamics.

Supply Chain Landscape

Raw Material Procurement

BASF

Kemira Oyj

Intermediate Production

DuPont de Nemours Inc

Bayer AG

Formulation
Mylan Pharmaceuticals Inc. / Teva Pharmaceutical Industries Ltd
Distribution & End-use
Pharmaceutical Stores / Online Pharmacies / Hospitals
Raw Material Procurement

BASF

Kemira Oyj

Intermediate Production

DuPont de Nemours Inc

Bayer AG

Formulation

Mylan Pharmaceuticals Inc.

Teva Pharmaceutical Industries Ltd

Distribution & End-use

Pharmaceutical Stores

Online Pharmacies

Hospitals

Banner LogoBanner Logo

Leading Providers and Their Strategies

Application AreaIndustryLeading Providers / ConsumersProvider Strategies
ADHD Treatment
Pharmaceutical & Healthcare
Eli Lilly and Company
Development of unique formulations and dosage strengths to optimize patient outcomes
Hypertension Management
Pharmaceutical & Healthcare
Novartis AG
Focus on innovative delivery systems to improve drug efficacy and patient compliance
Neuropsychiatric Disorders Therapy
Pharmaceutical & Healthcare
Pfizer Inc.
Investment in advanced R&D to deliver superior solutions for complex neuropsychiatric conditions

Elevate your strategic vision with in-depth analysis of key applications, leading market players, and their strategies. The report analyzes industry leaders' views and statements on the Guanfacine Hydrochloride market's present and future growth.

Our research is created following strict editorial standards. See our Editorial Policy

Applications of Guanfacine Hydrochloride in Attention Deficit Hyperactivity Disorder (ADHD) Management, Severe Pain Management and Treatment for High Blood Pressure

Attention Deficit Hyperactivity Disorder (ADHD) Management

Guanfacine Hydrochloride is also used in the management of Attention Deficit Hyperactivity Disorder, particularly in pediatric patients. The extended-release form has been found to be effective in controlling hyperactive and impulsive behaviors and in enhancing attention spans. The top players in this field are both generic and branded drug manufacturers that have secured a strong market position through effective medications and strategic partnerships with healthcare providers.

Severe Pain Management

Another significant application of Guanfacine Hydrochloride is in the management of severe pain. Certain formulations of the drug, when used as adjunct therapy to opioids, provide enhanced pain relief especially for neuropathic pain. The dominant players in this sector are manufacturers and distributors specializing in pain management medications. Their strength lies in their diverse product portfolio and their capacities to meet the high demand for comprehensive pain relief solutions.

Treatment for High Blood Pressure

Guanfacine Hydrochloride is regularly used in the treatment of high blood pressure. In this application, the oral form of the medication aids in reducing cardiovascular risks, easing the workload on the heart by decreasing heart rate and relaxing blood vessels to facilitate smoother blood flow. Top players in this region include branded pharmaceutical manufacturers who invest heavily in the research and development of higher potency formulations. Their market position is solidified by their consistent production of effective and reliable medications for hypertensive patients.

Guanfacine Hydrochloride vs. Substitutes:
Performance and Positioning Analysis

Guanfacine Hydrochloride stands significantly apart from its alternatives, offering fewer adverse side effects while ensuring efficient treatment for ADHD. Its unique market positioning arises from its superior safety profile, promising potential growth

Guanfacine Hydrochloride
  • Clonidine Hydrochloride /
  • Atomoxetine Hydrochloride
    Effective in treating attention deficit hyperactivity disorder (ADHD), has fewer side effects compared to other drugs
    May cause drowsiness, needs regular monitoring to check blood pressure levels
    Effective symptomatic relief, minimal side effects
    Potential for dependency, withdrawal symptoms

Guanfacine Hydrochloride vs. Substitutes:
Performance and Positioning Analysis

Guanfacine Hydrochloride

  • Effective in treating attention deficit hyperactivity disorder (ADHD), has fewer side effects compared to other drugs
  • May cause drowsiness, needs regular monitoring to check blood pressure levels

Clonidine Hydrochloride / Atomoxetine Hydrochloride / Methylphenidate Hydrochloride

  • Effective symptomatic relief, minimal side effects
  • Potential for dependency, withdrawal symptoms

Guanfacine Hydrochloride stands significantly apart from its alternatives, offering fewer adverse side effects while ensuring efficient treatment for ADHD. Its unique market positioning arises from its superior safety profile, promising potential growth

Loading...

Research Methodology

This market research methodology defines the Guanfacine Hydrochloride market scope, gathers reliable data, and validates findings using integrated primary and secondary research. Our systematic framework ensures precise market sizing, growth trend analysis, and competitive benchmarking.


Secondary Research Approach


We begin secondary research by defining the targeted market at Country and Regional levels. As part of the Pharmaceutical ecosystem, we analyze Guanfacine Hydrochloride across ADHD, Hypertension, and Anxiety Disorders Applications. Our team gathers data systematically from country level ministerial sources, industry associations & federations, trade databases, company annual & quarterly reports and other credential sources, enabling us to map global and regional market size, pricing trends, regulatory standards, and technology advancements.


Key Sources Referenced:


We benchmark competitors such as Amneal Pharmaceuticals LLC, Par Pharmaceutical Companies Inc, and Teva Pharmaceuticals USA Inc by reviewing company financial statements, and regulatory filings. Our secondary insights identify key market drivers and constraints, forming the analytical foundation for primary research.


Primary Research Methods


We conduct structured interviews and surveys with industry stakeholders, including Raw Material Procurement, Intermediate Production, and Formulation. Our geographic coverage spans Americas (40%), Europe (30%), Asia-Pacific (25%) and Middle East & Africa (5%). Our online surveys generally achieve a response rate of above 65%, and telephone interviews yield 60%, resulting in above 92% confidence level with a ±7% margin of error.


Through targeted questionnaires and in-depth interviews, we capture purchase intent, adoption barriers, brand perception across Segment Type. We use interview guides to ensure consistency and anonymous survey options to mitigate response bias. These primary insights validate secondary findings and align market sizing with real-world conditions.


Market Engineering & Data Analysis Framework


Our data analysis framework integrates Top-Down, Bottom-Up, and Company Market Share approaches to estimate and project market size with precision.


Top-down & Bottom-Up Process


In Top-down approach, we disaggregate global Pharmaceutical revenues to estimate the Guanfacine Hydrochloride segment, using historical growth patterns to set baseline trends. Simultaneously, in Bottom-up approach, we aggregate Country-Level Demand Data to derive regional and global forecasts, which provide granular consumption insights. By reconciling both approaches, we ensure statistical precision and cross-validation accuracy.


We evaluate the supply chain, spanning Raw Material Procurement (BASF, Kemira Oyj), Intermediate Production (DuPont de Nemours Inc, Bayer AG), and Formulation. Our parallel substitute analysis examines Clonidine Hydrochloride, Atomoxetine Hydrochloride, and Methylphenidate Hydrochloride, highlighting diversification opportunities and competitive risks.


Company Market Share & Benchmarking


We benchmark leading companies such as Amneal Pharmaceuticals LLC, Par Pharmaceutical Companies Inc, and Teva Pharmaceuticals USA Inc, analyzing their capabilities in pricing, product features, technology adoption, and distribution reach. By assessing company-level revenues and product portfolios, we derive market share comparisons, clarifying competitive positioning and growth trajectories across the ecosystem.


Our integration of data triangulation, supply chain evaluation, and company benchmarking, supported by our proprietary Directional Superposition methodology enables us to deliver precise forecasts and actionable strategic insights into the Guanfacine Hydrochloride market.


Quality Assurance and Compliance


We cross-reference secondary data with primary inputs and external expert reviews to confirm consistency. Further, we use stratified sampling, anonymous surveys, third-party interviews, and time-based sampling to reduce bias and strengthen our results.


Our methodology is developed in alignment with ISO 20252 standards and ICC/ESOMAR guidelines for research ethics. The study methodology follows globally recognized frameworks such as ISO 20252 and ICC codes of practice.

rm

Guanfacine Hydrochloride Market Data: Size, Segmentation & Growth Forecast

Report AttributeDetails
Market Value in 2025USD 540 million
Revenue Forecast in 2034USD 1.13 billion
Growth RateCAGR of 8.5% from 2025 to 2034
Base Year for Estimation2024
Industry Revenue 2024498 million
Growth OpportunityUSD 628 million
Historical Data2019 - 2023
Growth Projection / Forecast Period2025 - 2034
Market Size UnitsMarket Revenue in USD million and Industry Statistics
Market Size 2024498 million USD
Market Size 2027636 million USD
Market Size 2029749 million USD
Market Size 2030812 million USD
Market Size 20341.13 billion USD
Market Size 20351.22 billion USD
Report CoverageMarket revenue for past 5 years and forecast for future 10 years, Competitive Analysis & Company Market Share, Strategic Insights & trends
Segments CoveredPrescription Type, Application Areas, Patient Demographics, Therapy Type, Distribution Channel
Regional scopeNorth America, Europe, Asia Pacific, Latin America and Middle East & Africa
Country scopeU.S., Canada, Mexico, UK, Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Mexico, Argentina, Saudi Arabia, UAE and South Africa
Companies ProfiledAmneal Pharmaceuticals LLC, Par Pharmaceutical Companies Inc, Teva Pharmaceuticals USA Inc, Northstar Rx LLC, Mylan Pharmaceuticals Inc, Aurobindo Pharma Ltd, Wockhardt Ltd, Lupin Pharmaceuticals Inc, Mallinckrodt Inc, UDL Laboratories Inc, Actavis Pharma Inc and Sun Pharmaceutical Industries Ltd.
CustomizationFree customization at segment, region or country scope and direct contact with report analyst team for 10 to 20 working hours for any additional niche requirement which is almost equivalent to 10% of report value

Explore Report Features and Data Packages

Industry Insight Report

$ 4200
Unlock Multi-User Access for just $999 more
i
No Payment Before Report Delivery
Flexible Payment Options
Additional Features
Customization Available
i
Excel Data Pack Included
Free Analyst Support
i
Industry Expert-Validated Insights
100% Confidentiality Guaranteed
Fast Delivery (24–72 hours)
i
Get Report Now

Strategic Growth Advisory

Unrivaled Custom Market Intelligence & Strategic Advisory for Business Growth and Competitive Excellence

  • Assess and prioritize high-value markets with precision
  • Craft tailored entry and expansion roadmaps
  • De-risk investments through rigorous market intelligence
  • Architect dynamic pricing frameworks aligned to value creation
  • Unlock sustainable margin enhancement opportunities
  • Benchmark performance against global industry leaders
  • Strategically realign portfolios to future growth drivers
  • Accelerate commercialization of breakthrough offerings
  • Harness market foresight and technology shifts to fuel innovation

Discover our Strategic Growth Advisory Services »

Table of Contents

Industry Insights Report - Table Of Contents

Chapter 1

Executive Summary

Major Markets & Their Performance - Statistical Snapshots

Chapter 2

Research Methodology

2.1Axioms & Postulates
2.2Market Introduction & Research MethodologyEstimation & Forecast Parameters / Major Databases & Sources
Chapter 3

Market Dynamics

3.1Market OverviewDrivers / Restraints / Opportunities / M4 Factors
3.2Market Trends
3.2.1Introduction & Narratives
3.2.2Market Trends - Impact Analysis(Short, Medium & Long Term Impacts)
3.3Supply Chain Analysis
3.4Porter's Five ForcesSuppliers & Buyers' Bargaining Power, Threat of Substitution & New Market Entrants, Competitive Rivalry
Chapter 4

Guanfacine Hydrochloride Market Size, Opportunities & Strategic Insights, by Prescription Type

4.1Extended-Release
4.2Immediate-Release
Chapter 5

Guanfacine Hydrochloride Market Size, Opportunities & Strategic Insights, by Application Areas

5.1ADHD
5.2Hypertension
5.3Anxiety Disorders
5.4Sleep Disorders
5.5Other CNS Disorders
Chapter 6

Guanfacine Hydrochloride Market Size, Opportunities & Strategic Insights, by Patient Demographics

6.16–17 years
6.218 Years & Above
Chapter 7

Guanfacine Hydrochloride Market Size, Opportunities & Strategic Insights, by Therapy Type

7.1Monotherapy
7.2Combination Therapy
Chapter 8

Guanfacine Hydrochloride Market Size, Opportunities & Strategic Insights, by Distribution Channel

8.1Retail Pharmacies
8.2Hospital Pharmacies
8.3Online Pharmacies
8.4Specialty Pharmacies
Chapter 9

Guanfacine Hydrochloride Market, by Region

9.1North America Guanfacine Hydrochloride Market Size, Opportunities, Key Trends & Strategic Insights
9.1.1U.S.
9.1.2Canada
9.2Europe Guanfacine Hydrochloride Market Size, Opportunities, Key Trends & Strategic Insights
9.2.1Germany
9.2.2France
9.2.3UK
9.2.4Italy
9.2.5The Netherlands
9.2.6Rest of EU
9.3Asia Pacific Guanfacine Hydrochloride Market Size, Opportunities, Key Trends & Strategic Insights
9.3.1China
9.3.2Japan
9.3.3South Korea
9.3.4India
9.3.5Australia
9.3.6Thailand
9.3.7Rest of APAC
9.4Middle East & Africa Guanfacine Hydrochloride Market Size, Opportunities, Key Trends & Strategic Insights
9.4.1Saudi Arabia
9.4.2United Arab Emirates
9.4.3South Africa
9.4.4Rest of MEA
9.5Latin America Guanfacine Hydrochloride Market Size, Opportunities, Key Trends & Strategic Insights
9.5.1Brazil
9.5.2Mexico
9.5.3Rest of LA
9.6CIS Guanfacine Hydrochloride Market Size, Opportunities, Key Trends & Strategic Insights
9.6.1Russia
9.6.2Rest of CIS
Chapter 10

Competitive Landscape

10.1Competitive Dashboard & Market Share Analysis
10.2Company Profiles (Overview, Financials, Developments, SWOT)
10.2.1Amneal Pharmaceuticals LLC
10.2.2Par Pharmaceutical Companies Inc
10.2.3Teva Pharmaceuticals USA Inc
10.2.4Northstar Rx LLC
10.2.5Mylan Pharmaceuticals Inc
10.2.6Aurobindo Pharma Ltd
10.2.7Wockhardt Ltd
10.2.8Lupin Pharmaceuticals Inc
10.2.9Mallinckrodt Inc
10.2.10UDL Laboratories Inc
10.2.11Actavis Pharma Inc
10.2.12Sun Pharmaceutical Industries Ltd.